Prioritization of Epilepsy Associated Candidate Genes by Convergent Analysis by Jia, Peilin et al.
Prioritization of Epilepsy Associated Candidate Genes by
Convergent Analysis
Peilin Jia
1,2,3, Jeffrey M. Ewers
4, Zhongming Zhao
1,2,3,5*
1Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, 2Department of Psychiatry, Vanderbilt
University School of Medicine, Nashville, Tennessee, United States of America, 3Bioinformatics Resource Center, Vanderbilt University School of Medicine, Nashville,
Tennessee, United States of America, 4School of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, 5Department of
Cancer Biology, Vanderbilt University, Nashville, Tennessee, United States of America
Abstract
Background: Epilepsy is a severe neurological disorder affecting a large number of individuals, yet the underlying genetic
risk factors for epilepsy remain unclear. Recent studies have revealed several recurrent copy number variations (CNVs) that
are more likely to be associated with epilepsy. The responsible gene(s) within these regions have yet to be definitively linked
to the disorder, and the implications of their interactions are not fully understood. Identification of these genes may
contribute to a better pathological understanding of epilepsy, and serve to implicate novel therapeutic targets for further
research.
Methodology/Principal Findings: In this study, we examined genes within heterozygous deletion regions identified in a
recent large-scale study, encompassing a diverse spectrum of epileptic syndromes. By integrating additional protein-protein
interaction data, we constructed subnetworks for these CNV-region genes and also those previously studied for epilepsy.
We observed 20 genes common to both networks, primarily concentrated within a small molecular network populated by
GABA receptor, BDNF/MAPK signaling, and estrogen receptor genes. From among the hundreds of genes in the initial
networks, these were designated by convergent evidence for their likely association with epilepsy. Importantly, the
identified molecular network was found to contain complex interrelationships, providing further insight into epilepsy’s
underlying pathology. We further performed pathway enrichment and crosstalk analysis and revealed a functional map
which indicates the significant enrichment of closely related neurological, immune, and kinase regulatory pathways.
Conclusions/Significance: The convergent framework we proposed here provides a unique and powerful approach to
screening and identifying promising disease genes out of typically hundreds to thousands of genes in disease-related CNV-
regions. Our network and pathway analysis provides important implications for the underlying molecular mechanisms for
epilepsy. The strategy can be applied for the study of other complex diseases.
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Introduction
Epilepsy is a brain disorder involving recurrent seizures of any
type, and is one of the most common neurological disorders
affecting young people. Despite numerous efforts to elucidate its
pathological basis,the genetic andenvironmental factors underlying
epilepsy have remained unclear, a fact that may be partially
attributable to the complex subtypes of the disorder. Current studies
in the field, including genome-wide association (GWA) studies of
other neurological disorders, have suggested that rare variants, such
as large deletions or duplications, may play important roles in the
pathogenesis of similarly complex diseases [1].
A number of studies aiming to identify such rare variants have
been conducted, and have successfully revealed several loci and
genes conferring susceptibility to epilepsy, such as deletions at
15q13.3 [2] and 16p13.11 [3]. The association of copy number
variations (CNVs) with epilepsy has gained recent attention, and
has served to expand our knowledge of epileptic pathogenesis.
However, these CNV regions are typically large and contain many
genes, so it is not surprising that it still remains unclear which are
responsible for the disease [4]. To effectively approach the
prioritization of these candidate genes, one can incorporate
evidence from both the transcriptome and proteome level, in
order to investigate the genetic signals interactively and system-
atically [5–6].
To this end we performed an integrative analysis of CNV data,
gene association data accessed via the HuGE Navigator [7],
protein-protein interaction (PPI) data, and gene expression data.
By applying a graphic algorithm, we constructed subnetworks for
CNV genes and for previously studied genes separately, in the
context of the whole human PPI network. A comparison of the
genes comprising the two networks revealed 20 overlapping genes,
which hold high priority as candidates for epilepsy. Most of these
candidate genes could connect in a molecular network featuring
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signaling pathways. Incorporation of an expression dataset from
Gene Expression Omnibus (GEO) further highlighted two genes,
CHRNA7 and GABRA1, which are differently expressed between
epilepsy patients and controls. Finally, we performed pathway
enrichment analysis of the two subnetworks, followed by
examination of crosstalk between enriched pathways. These
results showed that neurotransmitter related pathways, immune
related pathways, and kinase regulatory pathways are significantly
enriched and clustered into functional groups.
Materials and Methods
Data sources
Copy number variation data was collected from a recently
published study, which conducted genome-wide screening of
CNVs for epilepsy disorders [3]. A total of 3812 patients with a
diverse spectrum of epilepsy syndromes and 1299 neurologically
normal controls were genotyped primarily using the Illumina
Human 610-Quad genome-wide genotyping array. We collected
373 genes (denoted as ‘‘CNV-genes’’) that were located in the
heterozygous deletion regions greater than 1 Mb observed in
epilepsy patients (see Table 1 in ref. [3]). As reported in the
original work, genes fully or partially covered by these regions
were listed and thus used in our analysis.
The HuGE Navigator is an integrated knowledge base of
human genome epidemiology, focusing primarily on the continual
collection of epidemiologic and genetic studies, including publica-
tions of genetic variants, gene-disease associations and gene-gene
or gene-environment interactions [7]. We specifically searched the
Phenopedia page for epilepsy related association studies and
reported genes. Using the exact match of term ‘‘epilepsy’’, we
retrieved 165 genes annotated in the HuGE database (as of April
23, 2010). We also checked other epilepsy related keywords (e.g.,
‘‘epilepsies, myoclonic’’) to search the HuGE database and could
only find a small number of genes, most of which were already
included in the 165 gene list. Thus, the 165 genes (hereafter
denoted as ‘‘HuGE-genes’’) were included in our analysis.
Specifically, Heinzen’s data was not included in the HuGE
database at the time we retrieved the data, thus, the two gene sets
are independent. Of note, the HuGE database collects published
genetic studies without distinguishing positive or negative
associations. Because replication rate of association is very low in
psychiatric genetics [8], and we attempted to include potential
candidate genes for convergent analysis, we included all of them in
this work.
We downloaded a comprehensive human PPI dataset from the
PINA platform (http://csbi.ltdk.helsinki.fi/pina/). PINA collected
and manually curated PPI data from six major PPI databases
(HPRD, IntAct, DIP, MINT, BioGRID, and MIPS/MPact) and
its data was derived from high-throughput experiments and
literature supported by experiments. Approximately 10,000 nodes
and ,50,000 interactions were included in the dataset as of
August, 2009. We used this dataset to construct a human PPI
network (i.e., interactome), upon which we performed follow-up
subnetwork analysis.
Subnetwork construction
We sought to identify connections among the CNV-genes and
HuGE-genes, hypothesizing that genes susceptible to epilepsy
would not be working independently, but instead would interact
with one another. We used the Steiner minimum tree algorithm
[9] to search for subnetworks in the human PPI network to
highlight genes of interest. The Steiner tree algorithm was initially
designed for searching a weighted network, and aims to determine
the least cost connected subgraph spanning a gene subset of special
interest. A detailed description of the algorithm can be found in
the original work [9]. In our application, since our PPI network is
unweighted, the execution of Steiner tree was simplified to
construct a connected subgraph spanning a maximum proportion
of our interesting nodes, e.g., the encoded proteins of CNV-genes
or HuGE-genes, and impeded by the restriction of minimizing the
nodes not belonging to the interesting nodes.
Integration with expression data
To integrate gene expression information, we downloaded an
expression dataset from GEO (http://www.ncbi.nlm.nih.gov/geo/,
accession number: GSE20977). This dataset was also part of
Heinzen’s work [3]. Blood samples from 7 epilepsy patients with
16p13.11 heterozygousdeletions and 8 normalcontrolswere studied
to estimate gene expression levels using Illumina Human HT-12 v3
microarrays [3]. The initial aim of this dataset was to evaluate the
impact of the deletion on gene expression. The data had been
previously normalized using robust spline normalization, and probes
withthe maximumintensitywerechosento represent eachgene.We
used a two-sided t-test to identify significant differentially expressed
genes between epilepsy patients and controls.
Pathway enrichment and pathway crosstalk
We used the Ingenuity Pathway Analysis (IPA) system (http://
www.ingenuity.com) to perform pathway enrichment tests. To
compute a P value for each pathway, IPA implements Fisher’s
exact test. We defined significant pathways as those with the
number of genes of interest $5 and P value ,0.01.
For pathway crosstalk, we considered paired pathways with no less
than 3 overlapping genes. To measure the gene-set overlap score, we
followed the algorithm proposed by enrichment map, a package for
Cytoscape [10], and investigated two measures of gene-set overlap:
the Jaccard Coefficient JC~
A\B jj
A|B jj
, and Overlap Coefficient
OC~
A\B jj
min A jj , B jj ðÞ
,w h e r eA and B denote two pathways. We took
the average of the two measurements as the score defining pathway
crosstalk, represented visually as a graph [11].
Table 1. Function enrichment of the subnetwork genes.
Diseases and disorders P-value
a #molecules
CNV-subnetwork
Neurological disease 9.41610
211–3.56610
25 132
Cancer 2.22610
210–5.70610
25 102
Genetic disorder 1.23610
29–7.60610
26 176
Psychological disorders 1.23610
29–3.24610
25 57
Reproductive system disease 2.22610
29–4.78610
25 49
HuGE-subnetwork
Neurological disease 2.02610
252–5.62610
27 143
Genetic disorder 4.47610
237–5.15610
27 165
Psychological disorders 4.34610
227–4.79610
27 81
Skeletal and muscular disorders 1.54610
225–5.15610
27 112
Organismal injury and abnormalities 9.49610
220–5.92610
27 54
aP-values were calculated by Fisher’s exact test, indicating probability of the
association of the candidate genes with the canonical pathway from chance.
Each disease category has several pathways, thus, the range of their P-values is
provided.
doi:10.1371/journal.pone.0017162.t001
Convergent Analysis of Epilepsy Candidate Genes
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Figure 1 illustrates our stepwise procedure to reduce the pool of
CNV-genes. Starting with two gene sets (i.e., CNV-genes and
HuGE-genes), we first constructed subnetworks for either gene set
by incorporating an established human interactome and imple-
menting a Steiner minimum tree algorithm. Comparison of the
two subnetworks revealed 20 overlapping genes of high priority.
We investigated the function and relationships of these 20 genes,
and further incorporated gene expression data to highlight two
genes deemed by our evidence as most relevant to epilepsy. To
further provide insights on the functional level, we then performed
pathway enrichment of genes in the resultant subnetworks,
examined crosstalk quantitatively between significant pathways,
and organized them in a graphical functional map.
Subnetwork construction of CNV-genes and HuGE-genes
There are 373 CNV genes reported in Heinzen’s work [3]. The
constructed CNV-subnetwork using the Steiner minimum tree
algorithm contains two types of nodes: 149 are of CNV-genes that
could be connected using the Steiner tree algorithm, and 126 were
additionally recruited in the process of subnetwork construction.
The remaining CNV-genes either lacked annotated interactions
with other proteins in the PPI network or would have included too
many unrelated nodes to connect them, thus, they were not
included for further analysis.
The same procedure was performed for HuGE-genes. As of
April 23, 2010, there were 165 genes annotated by HuGE as
related to epilepsy. Using the Steiner tree algorithm, we analyzed
these genes and constructed a HuGE-subnetwork containing 202
nodes, 127 of which belonged to the initial HuGE-gene list, while
75 were recruited additionally.
High-priority candidate genes from both subnetworks
On the gene level, we identified 20 genes in common between
the two subnetworks, and assigned them high-priority (Table 1) as
candidate genes for epilepsy. Five genes, ABCB1, ABCB4,
CHRNA7, GABRA1, and GABRG2, are located within reported
CNV regions and have been studied previously for their
association with epilepsy as collected by HuGE. AGL and
AP4M1 were found only within CNV genes, while ATXN1, BDNF
and NPY were annotated solely in HuGE. The other genes are
neither located in CNV regions nor collected by HuGE. They
were identified during the process of constructing the subnetworks;
thus, they are important for the structure of both subnetworks. Of
note, the gene ankyrin 3, node of Ranvier (ankyrin G), or ANK3,
has been reported in previous GWA studies to be associated with
schizophrenia [12] and bipolar disorder [13].
Using the Network Analysis tool in the IPA system, we observed
that 17 of the overlapping 20 genes appear in the top network,
which is significant for functional association with ‘‘carbohydrate
metabolism, lipid metabolism, and molecular transport’’ (Figure 2).
Three genes, UBB, GABRA1,a n dGABRG2, are constituents of the
GABA signaling pathway and are connected with other molecules
through protein-protein interaction (e.g., GABRG2 and CANX) or
regulation of gene expression (e.g., GABRA1 was observed to
decrease the expression of BDNF). We also observed molecules and
complexes such as BDNF, MAPK1, PRKACA, and the NMDA
receptor, which are known to participate in diverse neurodevelop-
mental processes. Interestingly, several hormone-related proteins
andhormone receptorswerealsoincluded in the network,including
the estrogen receptor and neuropeptide Y (NPY).
CHRNA7 and GABRA1 as differently expressed genes
We used the microarray data to compare gene expression levels
between epilepsy patients and normal individuals. A two-sided t-
test was performed to identify genes showing significant differential
expression (DE genes). We identified 1278 genes having P , 0.05,
including three genes discussed in the original study: NDE1,
C16orf63 and KIAA0430 [3].
Tofurtherprioritizecandidategenesforepilepsy,weexaminedthe
expression levels of the genes in the subnetworks. A few of these genes
were found to be significantly differentially expressed between
epilepsy patients and normal controls, including 12 genes from the
CNV-enriched subnetwork and 12 genes from the HuGE subnet-
work. Interestingly, two of these genes appear in our list of high-
priority genes, namelyCHRNA7 (P=0.014) and GABRA1 (P=0.016).
Pathway enrichment and crosstalk
We used the Ingenuity Pathway Analysis (IPA) system to
analyze the CNV-subnetwork and HuGE-subnetwork, respective-
ly. In the ‘‘Disease and Disorder’’ category of IPA system,
‘‘neurological disease’’ is the most significant category for both
CNV-subnetwork and HuGE-subnetwork (Table 2), supporting
the hypothesis of the involvement of neurological dysfunction in
epilepsy. We also observed ‘‘genetic disorder’’ and ‘‘psychological
disorders’’ as significant in both networks. While these results are
expected for the HuGE-genes, which were derived from previous
studies that often tested the neurological hypothesis of this disease,
the findings based on CNV-genes, which derived from an
unbiased genome-wide CNV dataset published recently and have
not been included in IPA yet, are important for understanding the
molecular mechanism of epilepsy.
In the pathway enrichment analysis, 129 canonical pathways
were nominally enriched in the CNV-subnetwork (Fisher’s exact
test, P , 0.01 and number of interesting genes $5, Table S1), and
75 in the HuGE-subnetwork (Table S2). We further investigated the
relationships among these pathways to identify general biological
features of epilepsy genes. Specifically, we examined crosstalk
among these pathways by computing overlap scores based upon
shared genes between any two pathways, and represented them
graphically using Cytoscape. In Figure 3,nodesrepresent significant
Figure 1. Convergent functional analysis of CNV genes for
epilepsy. PPI: protein-protein interaction. DE gene: differently
expressed genes in epilepsy patients and normal individuals.
doi:10.1371/journal.pone.0017162.g001
Convergent Analysis of Epilepsy Candidate Genes
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(i.e., represented as an edge) is established if two pathways share $3
genes, and is assigned a weight as the corresponding overlap score
(seeMaterialsandMethods), represented bythewidth oftheedgein
Figure 3. To highlight highly related pathways, only the top scored
connections and corresponding pathways are shown in Figure 3.
For CNV pathways, top scored connections are those scored within
the top 1%, while for HuGE pathways we included the top 5%
Figure 2. Molecular network of high-priority genes. Shaded nodes are genes from both CNV and HuGE networks. Green nodes are annotated
in association with epilepsy. Cyan nodes are annotated in association with schizophrenia. Red edges are from epilepsy nodes to nearest-neighbors.
Blue edges are from schizophrenia nodes to nearest-neighbors.
doi:10.1371/journal.pone.0017162.g002
Table 2. Evidence of high-priority candidate genes for epilepsy.
Gene symbol Gene name CNV-gene HuGE-gene
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 Y Y
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 Y Y
AGL Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase Y
ANK3 Ankyrin 3, node of Ranvier (ankyrin G)
AP4M1 Adaptor-related protein complex 4, mu 1 subunit Y
ATXN1 Ataxin 1 Y
BDNF Brain-derived neurotrophic factor Y
CANX Calnexin
CHRNA7 Cholinergic receptor, nicotinic, alpha 7 Y Y
GABRA1 Gamma-aminobutyric acid (GABA) A receptor, alpha 1 Y Y
GABRG2 Gamma-aminobutyric acid (GABA) A receptor, gamma 2 Y Y
HAX1 HCLS1 associated protein X-1
MAPK1 Mitogen-activated protein kinase 1
MDFI MyoD family inhibitor
NPY Neuropeptide Y Y
PRKACA Protein kinase, cAMP-dependent, catalytic, alpha
RXRA Retinoid X receptor, alpha
UBB Ubiquitin B
UBQLN4 Ubiquilin 4
doi:10.1371/journal.pone.0017162.t002
Convergent Analysis of Epilepsy Candidate Genes
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CNV-subnetwork. Figure 3 includes the resulting 40 pathways and
44 connections/edges from CNV-pathways and 47 pathways and
48 connections from HuGE-pathways. Four of the pathways were
overlapped.
Four groups were automatically formed by our analysis of
pathway crosstalk, which we termed ‘‘functional groups’’. As
shown in Figure 3, group 1 and group 2 are formed by the CNV-
and HuGE-subnetworks respectively, and each contains several
immune pathways and kinase regulatory pathways. IL-3 signaling,
IL-15 signaling, and IL-17 signaling were significantly enriched in
the CNV-subnetwork and clustered in group 1. Their crosstalk
involved JAK2, MAPK1, PIK3R1, and PIK3R3, which appear in
all three pathways and are included in the CNV-subnetwork.
Similarly, in group 2, which mainly consisted of HuGE-pathways,
IL-6 and IL-10 signaling pathways were observed and found to be
connected through the pathway ‘‘role of macrophages, fibroblasts
and endothelial cells in Rheumatoid Arthritis’’. No edge is
indicated between the IL-6 and IL-10 pathways because their
overlap score failed to meet the cutoff, but they share a number of
common genes, including IL1A, IL1B, IL1R1, IL1RN, IL6, and
TNF. Group 1 also contains the ERK/MAPK signaling pathway,
a pathway known to work in tandem with the BDNF/Trk
signaling pathway to regulate gene expression and trafficking
during central nervous system (CNS) development [14–15].
Within group 2, the p38 MAPK signaling pathway was also
observed. The HuGE-subnetwork also formed a group including
neurotransmitter pathways, such as the G-protein coupled
receptor and cAMP-mediated signaling pathways, and androgen
signaling pathways (group 4). The CNV-subnetwork formed a
group of several cancer pathways (group 3), which might be due to
the tendency of cancer genes to have more interactions with other
proteins in the PPI network, thus influencing their recruitment
during CNV-subnetwork construction.
Discussion
We collected four types of high-throughput datasets for epilepsy
disorders and performed integrative analysis using bioinformatics
Figure 3. Pathway crosstalk and functional map of the CNV-subnetwork and HuGE-subnetwork. We indicate each pathway as a gene
set. Significant pathways (nodes) are connected based on their overlap of component genes and are represented as edges. Node color indicates gene
set membership, i.e., green pathways are enriched in the CNV-subnetwork; blue pathways are enriched in the HuGE-subnetwork; purple pathways are
enriched in both subnetworks. Node size is proportional to the total number of encoded proteins of CNV-genes and HuGE-genes mapped in each
pathway. Edge width is proportional to the overlap score of the related pathways (see Materials and Methods). The legend in the bottom shows the
node size (i.e., the number of interesting proteins in each pathway) and edge width (i.e., the extent of the overlap between two nodes).
doi:10.1371/journal.pone.0017162.g003
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constructed PPI subnetworks enriched with CNV genes or
previously studied candidate genes for epilepsy. The overlap
between the two subnetworks comprised 20 genes, 17 of which
were included in a molecular network relevant to GABA signaling
and neurodevelopmental events. Interestingly, two of the overlap
genes, CHRNA7 and GABRA1, were also shown to be significantly
differentially expressed between epilepsy patients and normal
controls. Furthermore, functional enrichment of the two subnet-
works and examination of pathway crosstalk highlighted shared
‘‘neurological disease’’ in the disease category and immune/
kinase-regulatory/neurotransmitter related pathways in the ca-
nonical pathway category.
In the molecular network containing 17 of the 20 high priority
genes (Figure 2), we observed GABA signaling related genes,
BDNF/MAPK pathway genes, estrogen receptor and NPY and
their intimate interactions. Three genes from the GABA signaling
pathway, including two GABA A (GABAA) receptor subunits,
GABRA1 and GABRG2, were included. GABA is well studied as the
primary inhibitory neurotransmitter in mammalian brain, and
synaptic inhibition is largely mediated by fast activation of GABAA
receptors. Seizure is associated with imbalance of excitatory and
inhibitory synaptic activities, the latter of which is believed to be
associated with GABA, and deregulated expression and altered
function of GABAA receptors has been previously observed in
different types of epilepsy. For example, increased expression of
GABAA receptors was observed in the hippocampus of patients
with temporal lobe epilepsy [16–17], and an Ala322Asp mutation
in GABRA1 was found in juvenile myoclonic epilepsy patients
[18–19]. Additionally, many current pharmacological treatments
for epilepsy target elements of the GABA signaling pathway,
including GABA receptors and transporters. The observation of
GABRA1 and GABRG2 in our network provides strong evidence of
the association between GABAA receptors and epilepsy. GABRA1
was also identified to be differently expressed between epilepsy
patients and controls in our analysis of expression data.
BDNF is one of the neurotrophins, a large family that promote
the growth, survival, and differentiation of cells in the CNS. These
actions of neurotrophins are mediated by several cell surface
receptors including TrkA, TrkB and TrkC, which in turn activate
G-proteins and signaling cascades through intracellular tyrosine
kinase receptors and ultimately induce downstream gene expres-
sion and regulation. In our subnetwork, we observed an active
regulatory relationship between BDNF and MAPK1, which is also
a member of Erk1/2 dimer in MAPK/ERK signaling pathways.
These on some level reflect the complex role that BDNF may play
in epilepsy, e.g., increased expression of BDNF during seizures of
temporal lobe epilepsy patients as well as animal models have been
observed frequently, although it is not clear whether seizures or
injury increase expression of BDNF, or whether BDNF promotes
epileptogenesis by increasing excitability [20].
Within our top-scoring network (Figure 2), we also observed the
estrogen receptor and NPY. These inclusions are interesting given
prior hypotheses regarding the role of estrogen and neuropeptide
signaling in seizure disorders [21–22]. Estrogen, in particular, has
been previously implicated as a modulator of GABAergic function
[23]. Indeed, many antiepileptic therapies are known to interact
with estrogen signaling by inhibiting aromatase (e.g., oxacarbaze-
pine, phenobarbital, phenytoin, valproate) [24], linking estrogens
to globulins (e.g., carbamazepine) [25], or directly binding to
estrogen receptors (e.g., gabapentin) [26]. NPY, also included in
the network, has been shown to co-localize and interact with
estrogen [27–28]. NPY has been shown to play an important role
in GABAergic interneuron regulation of excitability, and has been
demonstrated to have neuroprotective effects against kainate-
induced excitotoxicity, both in vivo and in vitro [29–30]. Further
investigation of estrogen and NPY in relation to epilepsy may be
promising in the search for effective antiepileptic therapies.
Interestingly, within the network, we also observed several genes
previously reported to be associated with schizophrenia, including
ABCB1, ANK3, ATXN1, BDNF, CHRNA7, GABRA1, GABRG2,
NPY, and PRKACA [31], indicating their potential co-morbidity.
The co-morbidity between schizophrenia and epilepsy has been
aware for a long time by many aspects of the two diseases. For
example, genetic studies have shown that the human leucine-rich,
glioma inactivated family genes were linked to both epilepsy and
schizophrenia [32]; and anticonvulsant drugs have been widely
used in the treatment of psychiatric disorders. Among the genes we
identified, mutation of CHRNA7 has been observed in previous
schizophrenia studies [33]. CHRNA7 locates in 15q13.3, a region
having recurrent deletion reported in epilepsy [2], late-onset
Alzheimer’s disease [34], mental retardation [35], seizures [35],
and autism [36], among other pathologies. Furthermore, ANK3
has been found to be associated with schizophrenia [12] and
bipolar disorder [13]; however, to our knowledge, it has not been
well studied in epilepsy yet. These results may further help us to
understand the relations between epilepsy, schizophrenia, and
other psychiatric disorders.
Our pathway enrichment analysis of the two subnetworks and
the follow up investigation of pathway crosstalk revealed several
functional groups of interest. Of note, the pathway crosstalk map
showed more similarity between the two subnetworks on the level
of pathways and functional mechanisms than observed at the gene
level. For example, groups 1 and 2 consist of pathways from
different subnetworks, yet share a number of immune-related
pathways. These observations indicate the common involvement
of immune, neurotransmitter, and cell signaling pathways in
epilepsy, and reveal that close interactions between these pathways
allow for a system of complex regulation.
While genes from our CNV analysis were identified from large-
scale genotyping of epilepsy patients and can be considered as de
novo, the HuGE genes have been studied in previous publications
and are thus ‘‘known’’ candidate genes. The subset of genes
common to both lists is of particular interest, as it represents a
consensus between multiple lines of evidence. However, the
original gene lists shared only 5 genes, and their interrelationships
remain unclear. Using our network based method, we expanded
this overlap to 20 genes in the context of a PPI network, and
further demonstrated their relationship in a small molecular
network.
Many methods and approaches have been proposed to identify
disease candidate genes, such as single variant or gene analysis,
haplotype analysis, meta-analysis of variants, epistatic analysis,
genome-wide associate studies (GWAS), multiple dimensional
evidence-based approaches, and network and pathway approaches
[37–39]. While each of these methods has its advantages (e.g.,
GWA studies can examine one to several million SNPs at one
time), it also has some disadvantages. For example, analysis of
individual variants or genes could only detect genetic signal at one
specific locus. Many genes are expected to be involved in complex
diseases such as psychiatric disorders, but their risk might be too
moderate or weak to be detected in a typical association study. On
the other hand, most computational approaches to identifying or
predicting disease genes require a pre-defined set of ‘‘golden
standard genes’’[40]. Comparing with those methods, our
convergent strategy does not rely on golden standard genes, while
it examines many genes simultaneously. Although it has limitations
such as incompleteness of the dataset, it provides an alternative
Convergent Analysis of Epilepsy Candidate Genes
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genes from a variety of genetic and genomic datasets.
As above, a potential limitation of our work is the incomplete-
ness of the datasets we used. For example, caution should be taken
when using all the available ‘‘disease genes’’ in the HuGE
database, as some might represent negative results and cause noise
in convergent analysis. Furthermore, the CNV regions used in our
study were greater than 1 Mb in length. There might also be
important genes in smaller regions or in deleted regions, which
were not immediately available from the original publication [3].
However, the CNV regions we used in the current study were
directly from the original publication and were of high quality [3].
Nevertheless, our convergent strategy was able to identify 20 high-
priority genes within strong biological context. Inclusion of more
complete datasets or other types of datasets in future will greatly
improve the quality of the current work.
In conclusion, we proposed a stepwise enrichment procedure to
converge CNV genes by incorporating publically available high-
throughput datasets. By applying a subnetwork construction
algorithm, we established a subnetwork for CNV genes, as well
as for a set of previously reported genes for epilepsy. The overlap
between the two subnetworks constitutes a high-priority candidate
gene set for epilepsy. Integration of additional gene expression
data further narrowed the candidate gene list to two of special
interest. This procedure is extensible to other disorders.
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